BIG PHARMA FAIL –
May 9, 2025 – The lawsuit, filed in 2014 alleged that Bristol-Myers Squibb and Sanofi failed to disclose that their drug was less effective in patients with certain liver-enzyme mutations more prevalent in people of Asian and Pacific Islander descent representing up to 30% of people who took the drug in Hawaii.
After the 2024 award, officials with the drugmakers said in a statement that they strongly disagree with the court’s penalty and that they would appeal the decision. “The unprecedented penalties awarded in this case are unwarranted and out of proportion,” the companies said. “The overwhelming body of scientific evidence demonstrates that Plavix is a safe and effective therapy, regardless of a patient’s race or genetics.”
The case, closely watched nationwide, raised concerns over racial disparities in pharmaceutical efficacy and transparency.
Green credited the Attorney General’s Office and outside counsel, including attorney Rick Fried, for their role in securing the deal.
